A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT
J. Clin. Invest. Jennifer L. Gommerman, et al. 112:755 doi:10.1172/JCI18648 [Go to this article.]

Figure 1
Disease is prevented by LTβR-Ig or anti-LTβ treatment in an acute rat EAE model. (a) Lewis rats were treated with either control human IgG (diamonds), LTβR-Ig (circles), or N297Q LTβR-Ig (squares) 1 day prior to immunization with MBP-peptide in CFA, and disease was scored by measuring tail and limb paralysis. (b) Dose response to LTβR-Ig was evaluated in the rat EAE model by administering LTβR-Ig at the indicated dose. The percentage of inhibition of disease was calculated by determining the decrease in clinical score on the peak day of disease. (c) Lewis rats were treated with either control huIgG (diamonds), HVEM-Ig (squares), anti-murine LTβ (open circles), or control mAb HA4/8 (filled circles) 1 day prior to immunization with MBP-peptide in CFA. Treatment with anti-LTβ and HA4/8 was continued on days 3, 5, and 7 after immunization. Eight animals were used for each group, and the experiment was performed three times with similar results. Experiments using anti-LTβ, HVEM-Ig, and HA4/8 were performed two times with similar results.